| IPOWatch | May Apply |
| Dilip Davda | May Apply |
Paras Healthcare has over 20 years of experience in the healthcare industry, having successfully treated over 2.1 million Patients through its 8 hospitals across India with the guidance of 2110+ doctors & nurses. The company operates across cardiac, neuro, liver transplant, kidney transplant, bone marrow transplant, extracorporeal membrane oxygenation (“ECMO”)-enabled, neonatal, paediatric, medical and surgical ICUs.
For medium- to long-term investment, this IPO might be a good fit. Overall, investors should carefully evaluate the company’s fundamentals, strengths, risks, and growth prospects before deciding whether to invest.
Strengths:
- Paras Healthcare is one of the largest healthcare providers in North India, Bihar, and Jharkhand, having established its first hospital in Gurugram, Haryana, to offer accessible, high-quality healthcare services.
- It has a strong focus on offering advanced medical treatments, tertiary and Quaternary Care, generating high contribution from CONGOR specialties.
- The firm is known to offer high-quality clinical care through experienced and nationally recognised doctors, supported by modern infrastructure.
- Its cloud-first digital ecosystem allows companies to manage hospital operations and improve patient services, enhancing clinical effectiveness, patient experience and operational efficiency.
Weaknesses:
- Paras Healthcare is highly dependent on doctors, nurses, other healthcare professionals, and housekeeping staff for its operations. Moreover, in FY26, the firm has experienced a high attrition rate of 60.38%. Unable to manage or reduce the attrition rate can adversely impact the overall business and financial condition.
- Out of the 8 hospitals, 5 are situated in North India, which generates around 66.07% of the company’s revenue in FY26. Any negative changes around these hospitals or the region can negatively impact the overall business and cash flow.
- In FY26, the company generates 74.70% of its revenue from cardiac sciences, oncology sciences, neuro sciences, gastro sciences, orthopedics and sports injury, and renal sciences (collectively, “CONGOR”) specialties. Any negative changes in the demand around these specialties can badly impact the overall business and financial condition.
Disclaimer
Investors are advised to make their own decisions and apply entirely at their own risk. This article is written using information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.